Can patients stop treatment? lupus drug trial tests withdrawal

NCT ID NCT06711887

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This 2-year extension study follows patients with lupus nephritis, a serious kidney disease caused by lupus, who completed an earlier trial. It aims to see if patients who improved can safely stop taking the study drug (ianalumab) without their disease flaring up, and to continue monitoring the safety of the drug in others. The study will help understand the long-term control of this chronic condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Salvador, Estado de Bahia, 40150 150, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Shantou, Guangdong, 515000, China
Novartis Investigative Site
RECRUITING

Liuchow, Guangxi, 545005, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430060, China
Novartis Investigative Site
RECRUITING

Binzhou, Shandong, 256603, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Guangzhou, 510080, China
Novartis Investigative Site
RECRUITING

Guangzhou, 510280, China
Novartis Investigative Site
RECRUITING

Shanghai, 200080, China
Novartis Investigative Site
RECRUITING

Barranquilla, Atlántico, 080020, Colombia
Novartis Investigative Site
RECRUITING

Budapest, H-1097, Hungary
Novartis Investigative Site
RECRUITING

León, Guanajuato, 37160, Mexico
Novartis Investigative Site
RECRUITING

Oaxaca City, 68020, Mexico
Novartis Investigative Site
RECRUITING

Querétaro, 76070, Mexico
Novartis Investigative Site
RECRUITING

Bucharest, 022328, Romania
Novartis Investigative Site
RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
RECRUITING

Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Suwon, Gyeonggi-do, 16499, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03722, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 04763, South Korea
Novartis Investigative Site
RECRUITING

Taichung, 40447, Taiwan
Novartis Investigative Site
RECRUITING

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site
RECRUITING

Bangkok, 10330, Thailand
Novartis Investigative Site
RECRUITING

Bangkok, 10400, Thailand
Novartis Investigative Site
RECRUITING

Chiang Mai, 50200, Thailand

Conditions

Explore the condition pages connected to this study.

LUPUS NEPHRITIS